Zivo Bioscience, Inc. · OTC:ZIVO
Zivo Bioscience — January 2025 Microcap Conference
17 slides from Zivo Bioscience's conference presentation, January 2025
Slide 1: Transformative Opportunities in Therapeutics & Nutrition
(OTCQB: ZIVO) Transformative Opportunities in Therapeutics & Nutrition January 2025
Slide 2: Disclaimer
Disclaimer SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These sta
Slide 3: Investment Overview
Investment Overview One Natural Source. Numerous Commercial Opportunities. Developing novel therapeutics and functional food ingredients to power immune health Currently Generating Revenue • Direct-to-consumer launch of Zivolife , a nutritional supplement for the human green powder and vegan protein
Slide 4: Development History
Development History ZivolifeTM product begins commercial direct-to- • Cultivation consumer sales via One common natural technology, 2022 – 2024: Commercial techniques improved www.zivo.life. cultivation development two value creating paths begins in late 2022 and • Commercial scale manufacturing in
Slide 5: ZIVO Bioscience At-a-Glance
ZIVO Bioscience At-a-Glance Nutrition Therapeutics • Growth and distribution of ZivolifeTM, ZIVO’s • Identification and development of extracts, fractions or proprietary whole algal biomass, for use as molecules derived from proprietary algal polyculture a food or food ingredient to leverage its uni
Slide 6: Nutrition: Zivolife – Proprietary Algal Biomass
Nutrition: Zivolife – Proprietary Algal Biomass Our first revenue-generating, commercially-available product $1.0 billion market by 2031 Global green powder market Background Zivolife is natural, non-GMO, and a source of plant-based protein, naturally occurring beta glucan and fiber Sustainable,
Slide 7: Nutrition: Committed Revenue Stream Grows with Scale
Nutrition: Committed Revenue Stream Grows with Scale 24,000 kg annual purchase commitment1 ZWorldwide is ZIVO’s global distribution partner, Algae production pond with an initial focus on North America scaling plans Commits to minimum annual volume purchases for 5 years ZWorldwide to purchase en
Slide 8: Nutrition: Significant Market Opportunity
Nutrition: Significant Market Opportunity Proprietary dried algal biomass as a food or food ingredient Nutritive compounds found in ZIVO algae include functional food ingredients proven to enhance overall health in humans Market Opportunity Cultivation Model $1.0 billion by 2031 Presently growing
Slide 9: Nutrition: Additional Nutritional Opportunities
Nutrition: Additional Nutritional Opportunities ZIVO will develop algae-based products to address other food, supplement, and cosmetic markets Geographic Expansion Adjacent Markets • Canada Cosmetics / Topicals • Europe • Serums / Creams Food or Supplement Ingredient • ROW • Cleansers • Gommage / Ma
Slide 10: Therapeutic: Significant Market Opportunity
Therapeutic: Significant Market Opportunity Biopharma products from Zivo proprietary assets feature broad therapeutic potential in animals and humans. Initial Commercial Application Market Overview Coccidiosis treatment designed to be introduced in poultry feed or drinking water - IP protected via
Slide 11: Therapeutic: Validated Efficacy as Coccidiosis Treatment
Therapeutic: Validated Efficacy as Coccidiosis Treatment More than 20 independent research trials to evaluate the efficacy of ZIVO’s bioactive compounds in the treatment of coccidiosis have been completed Validated efficacy and mechanism-of-action studies in poultry gut health Intestinal Damage Mi
Slide 12: Therapeutic: Avian Influenza Potential
Therapeutic: Avian Influenza Potential Proprietary active ingredients were evaluated in a trial for efficacy in mitigating the effects of Low Pathogenicity Avian Influenza (LPAI) Key findings of statistical significance from the study include: Reduction in viral titers (viral shedding) in infected
Slide 13: Therapeutic: Additional Opportunities
Therapeutic: Additional Opportunities ZIVO will expand products/technology into other therapeutic opportunities, and employ a business model to license proprietary molecules or bioproducts to monetize its intellectual property portfolio Poultry Other (Livestock) Porcine (Livestock) Bovine (Livestock
Slide 14: Recent Developments and Strategic Progress
Recent Developments and Strategic Progress Advancements in Coccidiosis Treatment: Exploration of Avian Influenza Applications: January 2024: Positive efficacy results from a 42-day December 2024: Preliminary studies indicated that validation study demonstrated the effectiveness of ZIVO's ZIVO's prop
Slide 15: Where ZIVO is Headed?
Where ZIVO is Headed? Nutrition Therapeutic Algal Biomass Molecules Extracts Compounds Dry Mixes Complexes Strategic Partnerships & Regional Distributors Poultry Digestive Health Establish regional distributorships Prospective licensing or joint development deal Find partners to create new mar
Slide 16: Leadership Team
Leadership Team John B. Payne – President and CEO Harlan L. Miller III, PhD – VP Technology and Global Supply Served on ZIVO’s Board since 2013 and Chairman since 2019. He Dr. Miller is a recognized expert in algal production systems, has a significant management experience in publicly-traded previo
Slide 17: Investment Recap
Investment Recap One Natural Source. Numerous Commercial Opportunities. Developing novel therapeutics and functional food ingredients to power immune health Currently Generating Revenue • DTC launch in June 2023 of Zivolife , a nutritional supplement for the human green powder and vegan protein mark